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Correspondence
Induction of Bladder Cancer by
N-Nitroso-Dibutylamine and
N-Nitrososo-Butanol-(4)-Butylamine
Sir,-In a series of 65 N-nitroso com-
pounds that have been screened for carcino-
genic activity in rats by Druckrey et al.
(1967), N-nitroso-dibutylamine was found
to be the only symmetrical dialkylnitrosa-
mine which induced cancer of the urinary
bladder. Similarly, the related N-nitroso-
butanol-(4)- butylamine (I) was reported to
be an even more potent and specific bladder
carcinogen, since cancer of this organ was
diagnosed in all 25 animals which had
received daily doses of the compound as low
as 20 mg/kg in drinking water (Druckrey et
al., 1964). The available evidence indicates
that the nitrosamines are metabolized into
potential alkyl donors and aldehydes (Magee
and Barnes, 1967) and their carcinogenic
activity has been attributed to alkylation of
biopolymers. The alkylating intermediates
have been thus regarded key metabolites in
nitrosamine carcinogenesis, whereas the func-
tional importance of the aldehydic fragments
has been hitherto neglected.
Experimental bladder cancer was induced
by nitrosamines substituted with n-C4 alkyl
groups only and the activity towards bladder
epithelium was greatly increased by the
presence ofan co-hydroxyl group in one ofthe
alkyl chains. It is therefore conceivable
that a unique metabolite which could be
derived from the structural elements of the
applied nitrosamine, was responsible for the
specific biological effect. On the assumption
that enzymic dealkylation is also an essential
step involved in the activation of N-nitroso-
butanol-(4)-butylamine, the fission of the
hydroxylated molecule would result in the
liberation of 4-hydroxybutanal (II) which
would readily cyclize to its tautomeric
hemiacetal, 2-hydroxytetrahydrofuran (III).
Subsequent oxidation of this intermediate
to y-butyrolactone can be easily envisaged.
Alternatively, and even more likely, in vivo
oxidation of the alcohol group in (I) to a
carboxyl (IV), followed by enzymic hydroxy-
lation and cleavage, would lead to the release
of 4-butanal-1-carboxylic acid (V) which
would also cyclize to its tautomeric lactol
(VI). The mechanistic feasibility of the
latter pathway is supported by a recent
finding of Okada (1972) that N-nitroso-
butanol-(4)-butylamine is metabolized in
the rat to N-nitroso-butanoic acid-(4)-buty-
lamine (IV) in 20% yield; this compound was
also shown to be a powerful bladder carcino-
gen. The existence of similar ring-chain
equilibria in biologically active molecules,
such as penicillic acid, is a well-known
phenomenon. The sequence of suggested
transformations is shown below.
The proposed metabolic pathway would
therefore establish a relationship between
the nitrosamines and the lactones which are
another class of known chemical carcinogens.
Since further in vivo modifications of the
applied nitrosamine can occur, the ultimate
carcinogen could well be a related lactone
derived from the modified C4 skeleton.
Despite much intensive research, the
molecular basis of chemical carcinogenesis
is still obscure, and any attempt to correlate
chemical structure with carcinogenic activity
is therefore a most difficult task. Neverthe-
less, the proposal that bladder carcinogenesis
by N-nitroso-dibutylamine and N-nitroso-
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butanol-(4)-butylamine could be the result
of conversion to an active oxygenated meta-
bolite, ratherthanalkylation, isalsosupported
by the isolation of the naturally occurring
bladder carcinogen from Pteridium aquilinum
by Leach et al. (1971). The most likely
structure for this carcinogen has been shown
to be a substituted five-membered lactone.
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